ArticleJournal of the National Cancer Institute2016

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Sinead Toomey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.